AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD | Market Cap | 627.01B +21.5% |
| Revenue (ttm) | 91.43B +10.4% |
| Net Income | 8.90B +67.7% |
| EPS | 5.03 +68.5% |
| Shares Out | n/a |
| PE Ratio | 70.42 |
| Forward PE | 16.93 |
| Dividend | 1.19 (3.34%) |
| Ex-Dividend Date | Jul 15, 2026 |
| Volume | 742 |
| Open | 35.99 |
| Previous Close | 36.25 |
| Day's Range | 35.63 - 35.99 |
| 52-Week Range | 26.89 - 37.16 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS
AbbVie (ABBV) announced positive topline results from the Phase 3 Cervino study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies, SAT,...
AbbVie's blood cancer drug meets late-stage trial goals
AbbVie said on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ra...
AbbVie completes acquisition of Apogee for $135.11 per share in cash
AbbVie (ABBV) announced that it has completed its acquisition of Apogee Therapeutics (APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement,…
AbbVie Completes Acquisition of Apogee Therapeutics
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is ...
AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026.
AbbVie’s Allergan expands SkinMedica’s portfolio with Barrier Calming Cream
Allergan Aesthetics, an AbbVie (ABBV) company, expands SkinMedica’s portfolio of regenerative skincare products with the launch of Barrier Calming Cream. “SkinMedica was a pioneer in regenerative skin...
SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks 1 SkinMedica ® also introduces HA 5® Hydra Collagen Facial Mist for easy, ...
AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.
AbbVie submits Skyrizi application to the EMA
AbbVie (ABBV) announced that it has submitted an application to the European Medicines Agency, or EMA, seeking approval for Skyrizi for subcutaneous induction for the treatment of adult patients with…
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for in...
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation Additionally, new dat...
AbbVie price target raised to $303 from $298 at Piper Sandler
Piper Sandler raised the firm’s price target on AbbVie (ABBV) to $303 from $298 and keeps an Overweight rating on the shares. The firm notes monthly third-party prescription data for…
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
Since its 2016 launch, hundreds of exceptional students pursuing higher education have received the scholarship Now a renewable award, students may earn the AbbVie Immunology Scholarship for up to fou...
AbbVie price target raised to $300 from $295 at Wells Fargo
Wells Fargo raised the firm’s price target on AbbVie (ABBV) to $300 from $295 and keeps an Overweight rating on the shares. The firm’s preview of the company’s second half…
AbbVie upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research analyst Alexandria Hammond upgraded AbbVie (ABBV) to Outperform from Peer Perform with a $300 price target The firm cites the company’s attractive valuation relative to peers and lack…
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
AbbVie price target raised to $260 from $246 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on AbbVie (ABBV) to $260 from $246 and keeps an Outperform rating on the shares.
AbbVie upgraded to Buy from Hold at Erste Group
Erste Group upgraded AbbVie (ABBV) to Buy from Hold. AbbVie recently raised its 2026 revenue forecast slightly and has made significant progress in its pipeline in the areas of immunology,…
AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA
Allergan Aesthetics, an AbbVie (ABBV) company, announced the FDA has accepted for review its supplemental Biologics License Application for Botox Cosmetic for the temporary improvement in the appearan...
AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic
Allergan Aesthetics, an AbbVie (ABBV) company, announced the U.S. FDA has accepted for review its supplemental Biologics License Application for Botox Cosmetic for the temporary improvement in the app...
Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
If approved, BOTOX ® Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission i...
AbbVie price target raised to $288 from $261 at Guggenheim
Guggenheim raised the firm’s price target on AbbVie (ABBV) to $288 from $261 and keeps a Buy rating on the shares. The firm updated its model for the “solid” Q2…
AbbVie price target raised to $285 from $265 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on AbbVie (ABBV) to $285 from $265 and keeps an Overweight rating on the shares. AbbVie delivered a strong quarter with broad-based beats,…